Equities

Control Bionics Ltd

CBL:ASX

Control Bionics Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.066
  • Today's Change0.001 / 1.54%
  • Shares traded612.00
  • 1 Year change+32.00%
  • Beta0.8091
Data delayed at least 20 minutes, as of Nov 15 2024 00:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of AUD
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments0.980.945.21
Total Receivables, Net1.401.981.48
Total Inventory0.400.800.92
Prepaid expenses0.140.15--
Other current assets, total0.83--0.99
Total current assets3.763.878.61
Property, plant & equipment, net1.220.720.73
Goodwill, net------
Intangibles, net4.054.114.07
Long term investments------
Note receivable - long term------
Other long term assets----0.02
Total assets9.038.7013
LIABILITIES
Accounts payable0.61--0.43
Accrued expenses0.170.23--
Notes payable/short-term debt0.5200.05
Current portion long-term debt/capital leases0.110.070.11
Other current liabilities, total0.59--0.59
Total current liabilities2.401.471.36
Total long term debt0.340.060.12
Total debt0.960.130.28
Deferred income tax------
Minority interest------
Other liabilities, total0.020.020.03
Total liabilities2.761.551.51
SHAREHOLDERS EQUITY
Common stock353029
Additional paid-in capital------
Retained earnings (accumulated deficit)(29)(23)(17)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.070.090.02
Total equity6.277.1512
Total liabilities & shareholders' equity9.038.7013
Total common shares outstanding19910096
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.